Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for the Treatment of Amyotrophic Lateral Sclerosis
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Umbilical cord-derived allogeneic mesenchymal stem cell therapy-Vitro Biopharma (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
Most Recent Events
- 17 Apr 2025 Planned End Date changed from 1 Sep 2025 to 1 Sep 2028.
- 17 Apr 2025 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2028.
- 17 Apr 2025 Planned initiation date changed to 1 Dec 2025.